Bilaterally-substituted tricyclic compounds for the treatment of human immunodeficiency virus type-1 (hiv-1) infection and other diseases

A compound of formula (I)

• or a pharmaceutical salt, ester, solvate, or hydrate thereof
• wherein
• A, B and C are benzene,
• R1 and R2 are in bilateral 1,3 disubstitution relative to each other in benzene A and meta in relation to the carbon atom of A attached to benzene B;
• and are independently selected from alkyl amine and alkyl guanidine;
• R3 and R4 are in bilateral 1,3 disubstitution relative to each other in benzene B and ortho in relation to the carbon atom of B attached to benzene A;
• and are independently selected from hydrogen, (C1-C6) alkylamide, (C1-C6) alkyl ester, (C1-C6) hydroxyalkyl, (C1-C6) haloalkyl, (C1-C6) alkoxyalkyl, (C1-C8) alkyl, provided that at least one of R3 and R4 is not hydrogen;
• R5 and R6 are in bilateral 1,3 disubstitution relative to each other in benzene C and ortho in relation to the carbon atom of C attached to benzene B;
• and are independently selected from alkyl amine and alkyl guanidine;
• R7 and R8 are independently selected from hydrogen, halogen, hydroxyl, (C1-C10) alkoxy, (C1-C10) alkyl amine, (C1-C10) alkyl guanidine, (C1-C10) alkyl amide, (C1-C10) alkylester, (C1-C10) hydroxyalkyl, (C1-C10) alkoxyalkyl, (C1-C10) haloalkyl, (C1-C10) alkyl, aryl alkoxy and aryl ester.